Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.
Identifieur interne : 000134 ( Ncbi/Curation ); précédent : 000133; suivant : 000135Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.
Auteurs : E. Mohr [Canada] ; T. Mendis ; K. Hildebrand ; P P De DeynSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.
Descripteurs français
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (adverse effects), Antipsychotic Agents (therapeutic use), Belgium, Canada, Dopamine (adverse effects), Dopamine Antagonists (therapeutic use), Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Pilot Projects, Psychiatric Status Rating Scales, Psychoses, Substance-Induced (drug therapy), Risperidone (therapeutic use), Treatment Outcome.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine.
- chemical , therapeutic use : Antipsychotic Agents, Dopamine Antagonists, Risperidone.
- geographic : Belgium, Canada.
- complications : Parkinson Disease.
- drug therapy : Parkinson Disease, Psychoses, Substance-Induced.
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Treatment Outcome.
Abstract
To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis.
PubMed: 11104211
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001609
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001609
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001609
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000134
Links to Exploration step
pubmed:11104211Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.</title><author><name sortKey="Mohr, E" sort="Mohr, E" uniqKey="Mohr E" first="E" last="Mohr">E. Mohr</name><affiliation wicri:level="1"><nlm:affiliation>CroMedica Global Inc., Victoria, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CroMedica Global Inc., Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Mendis, T" sort="Mendis, T" uniqKey="Mendis T" first="T" last="Mendis">T. Mendis</name></author><author><name sortKey="Hildebrand, K" sort="Hildebrand, K" uniqKey="Hildebrand K" first="K" last="Hildebrand">K. Hildebrand</name></author><author><name sortKey="De Deyn, P P" sort="De Deyn, P P" uniqKey="De Deyn P" first="P P" last="De Deyn">P P De Deyn</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:11104211</idno><idno type="pmid">11104211</idno><idno type="wicri:Area/PubMed/Corpus">001609</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001609</idno><idno type="wicri:Area/PubMed/Curation">001609</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001609</idno><idno type="wicri:Area/PubMed/Checkpoint">001609</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001609</idno><idno type="wicri:Area/Ncbi/Merge">000134</idno><idno type="wicri:Area/Ncbi/Curation">000134</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.</title><author><name sortKey="Mohr, E" sort="Mohr, E" uniqKey="Mohr E" first="E" last="Mohr">E. Mohr</name><affiliation wicri:level="1"><nlm:affiliation>CroMedica Global Inc., Victoria, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>CroMedica Global Inc., Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Mendis, T" sort="Mendis, T" uniqKey="Mendis T" first="T" last="Mendis">T. Mendis</name></author><author><name sortKey="Hildebrand, K" sort="Hildebrand, K" uniqKey="Hildebrand K" first="K" last="Hildebrand">K. Hildebrand</name></author><author><name sortKey="De Deyn, P P" sort="De Deyn, P P" uniqKey="De Deyn P" first="P P" last="De Deyn">P P De Deyn</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Belgium</term><term>Canada</term><term>Dopamine (adverse effects)</term><term>Dopamine Antagonists (therapeutic use)</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Pilot Projects</term><term>Psychiatric Status Rating Scales</term><term>Psychoses, Substance-Induced (drug therapy)</term><term>Risperidone (therapeutic use)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Dopamine Antagonists</term><term>Risperidone</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Belgium</term><term>Canada</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Dose-Response Relationship, Drug</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term><term>Psychiatric Status Rating Scales</term><term>Treatment Outcome</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Belgique</term><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000134 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000134 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:11104211
|texte= Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:11104211" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |